Impact of MenAfriVac in nine countries of the African meningitis belt, 2010-15: an analysis of surveillance data.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

In preparation for the introduction of MenAfriVac, a meningococcal group A conjugate vaccine developed for the African meningitis belt, an enhanced meningitis surveillance network was established. We analysed surveillance data on suspected and confirmed cases of meningitis to quantify vaccine impact.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Infect Dis

Title: The Lancet. Infectious diseases

Publisher: Elsevier BV

ISSN (Electronic): 1474-4457

ISSN (Print): 1473-3099

Publication date (Electronic): May 22 2017

Affiliations

[1 ] Disease Dynamics Unit, Department of Veterinary Medicine, University of Cambridge, Cambridge, UK. Electronic address: clt56@cam.ac.uk.

[2 ] Inter-country Support Team for West Africa, World Health Organization, Ouagadougou, Burkina Faso.

[3 ] Department of Pandemic and Epidemic Diseases, World Health Organization, Geneva, Switzerland.

[4 ] Disease Dynamics Unit, Department of Veterinary Medicine, University of Cambridge, Cambridge, UK.

[5 ] Immunization and Vaccine Development Unit, Regional Office for Africa, World Health Organization, Brazzaville, Congo.

[6 ] Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.

[7 ] Faculty of Infectious & Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.

Article

Publisher Item ID: S1473-3099(17)30301-8

DOI: 10.1016/S1473-3099(17)30301-8

PubMed ID: 28545721

SO-VID: 7d287c77-2c56-43f9-b64c-5a8e9dde339a

History

Data availability:

Comments

Comment on this article

scite_

Cited by 89

See all cited by